Business Wire

Tilray® Exports First Shipment of Medical Cannabis to Spain

Share

Tilray, Inc. (NASDAQ: TLRY), a global pioneer in cannabis research, cultivation, production, and distribution, today announced it has agreed with Worldpharma Biotech ("Worldpharma"), through its wholly-owned subsidiary Tilray Portugal Unipessoal Lda. (“Tilray Portugal”), to export Good Manufacturing Processes (GMP) certified medical cannabis from Portugal to Spain. The shipment marks the first medical cannabis import into Spain by Worldpharma and the 17th country to receive Tilray medical cannabis worldwide.

The Agencia Española de Medicamentos y Productos Sanitorios (AEMPS), Spain’s food and drug administration, has approved Worldpharma to import Tilray’s GMP-certified medical cannabis as raw material from its Portugal facility to Spain. With Tilray's pharmaceutical-grade cannabis, Worldpharma will develop medical cannabis products for clinical trials in Spanish Hospitals for diseases such as Alzheimer's, Parkinson’s disease, and skin inflammation.

Brendan Kennedy, Tilray’s Chief Executive Officer, said, “We’re incredibly honored to be the first cannabis company to be approved and to ship medical cannabis into Spain. As we continue to work with regulators around the world, we are grateful to partner with the AEMPS and established pharmaceutical leaders such as Worldpharma Biotech on the distribution of Tilray medical cannabis.”

Juan Jose Garcia Miquel, Founder of World Pharma Biotech, said, "We are very happy to initiate a cannabis biomass supply agreement with Tilray to supply our extraction and purification lab with quality GMP certified products that meet the highest of E.U. and Spanish Pharmacology Standards. We intend to work with the companies with the highest quality pharmaceutical standards to give doctors and patients total confidence. It's been impossible to reach this level of quality from other cannabis authorized companies in Spain.”

Sascha Mielcarek, Tilray’s General Manager for Europe, said, “We are very pleased to partner with Worldpharma. Tilray is once again establishing itself as a key player with solid expertise in the service of patient well-being. Throughout its supply chain, Tilray applies the highest medical standards that provide sustainable and safe access to pharmaceutical-grade medical cannabis for patients in need, paving the way for future medical cannabis standards of care.”

Tilray has a pioneering track record as a company committed to making GMP-certified, pharmaceutical-grade medical cannabis products available to patients in need worldwide and was the first to successfully export medical cannabis from North America and import medical cannabis products into the E.U. in 2016.

Tilray's E.U. Campus in Portugal is a multi-faceted production facility that includes research and quality control labs, packaging, and distribution sites for medical cannabis. It also serves as a hub supporting Tilray’s clinical research and product development efforts across Europe. Tilray has established sales and distribution arrangements to supply medical cannabis through major pharmaceutical distribution channels throughout Germany and the E.U., which will serve as a means to allowing patients to access Tilray's GMP-certified finished medical cannabis.

About Tilray®

Tilray is a global pioneer in the research, cultivation, production, and distribution of cannabis and cannabinoids, currently serving tens of thousands of patients and consumers in 17 countries spanning five continents.

About WorldPharma Biotech

World Pharma Biotech was founded in 2014 in Valencia, Spain, focused on vegetal ingredients for nutraceuticals, cosmetics, and pharmaceutical industries. The company is located in the Scientific Park of the University of Valencia, a center of Spin-off and Start-up companies from Valencia University. The extraction and purification lab's primary focus is the manufacturing of Active Pharmaceutical Ingredients from Cannabis for the European Pharmaceutical and Dermo Cosmetic Industry.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of Canadian securities laws, or collectively, forward-looking statements. Forward-looking statements in this press release may be identified by the use of words such as, "may", "would", "could", "will", "likely", "expect", "anticipate", "believe, "intend", "plan", "forecast", "project", "estimate", "outlook" and other similar expressions. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management's experience and perception of trends, current conditions, and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, including assumptions in respect of current and future European market conditions, the current and future regulatory environment and future approvals and permits. Actual results, performance, or achievement could differ materially from that expressed in, or implied by, any forward-looking statements in this press release, and, accordingly, you should not place undue reliance on any such forward-looking statements, and they are not guarantees of future results. Please see the heading "Risk Factors" in Tilray's Quarterly Report on Form 10-Q, which was filed with the Securities and Exchange Commission on November 9, 2020, for a discussion of the material risk factors that could cause actual results to differ materially from the forward-looking information. Tilray does not undertake to update any forward-looking statements that are included herein, except in accordance with applicable securities laws.

Contact information

For further information:
Tilray Global:
Berrin Noorata
news@tilray.com

To request an interview opportunity:
Media
Amy Bonwick
647-515-3748
amy@pomppr.com

Ranjit Dhatt
647-890-2445
ranjit@pomppr.com

Investors
Raphael Gross
203-682-8253
Raphael.Gross@icrinc.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Temenos and Canadian Western Bank Break the Boundaries of SME Banking with an Explainable AI Digital Banking Solution4.3.2021 16:00:00 EETPress release

Temenos (SIX: TEMN), the banking software company, today announced that it is partnering with Canadian Western Bank (CWB) on a pioneering innovation to support small- and medium-sized enterprises (SMEs) with financial decision-making and growing their businesses. The new solution, Temenos Virtual COO, is built on Temenos Infinity, the leading omnichannel digital banking product, and leverages Temenos Analytics and Explainable AI (XAI), API-first, cloud-native technology. Temenos Virtual COO will offer relevant insights to accelerate the growth of small businesses and put business owners in control of their companies’ financial destiny. SME owners will be able to simulate different business scenarios with XAI-driven modeling enabling them to identify the best course of action for their business. The new solution will aggregate financial banking and business data to provide a consolidated real-time view of an SME’s financial health, and lighten the administrative burden so that business

Data Presented at the Miami Breast Cancer Conference Show MammaPrint® and BluePrint® Accurately Predict Pathologic Complete Response Rate Regardless of Age4.3.2021 16:00:00 EETPress release

Agendia, Inc., a world leader in precision oncology for breast cancer, announced new data from the prospective Neoadjuvant Breast Symphony Trial (NBRST) which demonstrate the predictive and prognostic abilities of MammaPrint® and BluePrint®, and underpin both assays’ pre-operative utility in pre-and post-menopausal patients. A poster highlighting these findings will be presented at the 38th Annual Miami Breast Cancer Conference. The poster, entitled Pathologic Complete Response (pCR) Rates According to MammaPrint and BluePrint Results are Consistent Among Pre- and Post-Menopausal Patients, outlines the first age-based analyses of MammaPrint and BluePrint assays in the pre-operative setting. As expected, the data show that pCR rates varied according to molecular subtype, with MammaPrint and BluePrint accurately predicting pCR in patients of all subtypes, regardless of age. This analysis reinforces both tests’ use to better tailor pre-operative treatment and in determining the best timin

Square, Inc. Announces Plans to Acquire Majority Ownership Stake in Tidal4.3.2021 16:00:00 EETPress release

Square, Inc. (NYSE: SQ) announced today that it has entered into a definitive agreement to acquire a majority ownership stake in TIDAL, the global music and entertainment platform that brings fans and artists together through unique music, content, and experiences. Square expects to pay a mix of cash and stock of $297 million for a significant majority ownership stake, and existing artist shareholders will be the remaining stakeholders. TIDAL will operate independently within Square, alongside the Seller and Cash App ecosystems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210304005346/en/ Photo (from left to right): Shawn “JAY-Z” Carter, Jack Dorsey. Photo credit (from left to right): Raven Varona, Hermione Hodgson. The acquisition extends Square’s purpose of economic empowerment to a new vertical: musicians. Artists are entrepreneurs with a dream and deserve access to systems, tools, and financial freedom to reach those

Wipro to acquire Capco, a global management and technology consultancy to banking and financial services industry, for $ 1.45 billion4.3.2021 15:40:00 EETPress release

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced that it has signed an agreement to acquire Capco, a global management and technology consultancy providing digital, consulting and technology services to financial institutions in the Americas, Europe and the Asia Pacific. London-headquartered Capco’s clients include many marquee names in the global financial services industry. Over the past 20 years, the company has worked closely with business leaders, including Boards and C-Suites in the banking, capital markets, wealth, asset management and insurance sectors and is widely acknowledged for its deep domain and consulting expertise, risk and regulatory offerings and thought leadership around key industry technology challenges and opportunities. In addition, Capco services clients in the energy and commodities trading sector. Capco has an experienced executive team and over 5,000

Hopin Raises $400 Million to Scale Innovation for Hybrid Experiences4.3.2021 15:30:00 EETPress release

Hopin, a leading virtual events provider, announced today that it has raised $400M in Series C funding co-led by new investors Andreessen Horowitz and General Catalyst, and existing investor IVP, with participation from returning investors Coatue, DFJ Growth, Northzone, Salesforce Ventures and Tiger Global. The funding follows Hopin’s $125 million Series B funding announced in November 2020. Since then, Hopin has added 30,000 customers including Poshmark, American Express, Hewlett Packard, The Financial Times, and YMCA. Since February of last year, Hopin has raised more than $565 million. Johnny Boufarhat, CEO and Founder of Hopin said: “We are creating a portfolio of products to build the future of live video collaboration and remote community. As we’ve seen, the importance of providing unparalleled virtual and hybrid event experiences has never been greater and this latest funding is a reflection of how critical it is as brands look for ways to connect with people and avenues of grow

New Research Reveals More CROs Taking Action to Meet Urgent Need for Faster Clinical Trials4.3.2021 15:03:00 EETPress release

Contract research organizations (CROs) are making significant advancements to modernize and speed clinical trials, according to the latest Veeva Unified Clinical Operations Survey: Annual CRO Report. COVID-19 dramatically accelerated the need to execute faster and with greater precision than ever before. Findings from Veeva Systems (NYSE: VEEV) show CROs have taken decisive action to streamline trial execution by adopting new digital strategies and technologies that eliminate information siloes, replace manual processes, and enable trial collaboration. Nearly all CROs surveyed (90%) have major initiatives underway to unify clinical operations, a lynchpin to faster, more efficient research. The efforts to unify extended beyond CROs’ internal systems and processes. Streamlining collaboration and information sharing with research sites and sponsors was consistently cited by CROs as one of the highest priority areas overall and a key driver for the modernization efforts underway. In additi

DeepGreen, Developer of the World's Largest Estimated Resource of Battery Metals for EVs, to Combine with Sustainable Opportunities Acquisition Corporation4.3.2021 15:00:00 EETPress release

DeepGreen Metals Inc., a developer of lower-impact battery metals from unattached seafloor polymetallic nodules, today announced that it has entered into a definitive business combination agreement with Sustainable Opportunities Acquisition Corporation (NYSE: SOAC), a special purpose acquisition company with a dedicated ESG focus and deep operational and capital market capabilities in the energy and resource sectors. The transaction represents a pro forma equity value of US$2.9 billion (assuming no redemptions) for the combined company, which will be renamed “TMC the metals company Inc.” and operate as The Metals Company upon closing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210304005510/en/ Responsibly Sourcing Battery Metals to Address Looming Critical Shortage for EV Supply Chain DeepGreen is developing a new, scalable source of EV battery metals in the form of polymetallic nodules found unattached on the seafloor i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom